Weight Loss Wellness program with Semaglutide & TirzepatidE

In a 68-week medical study of 1,961 adults living with obesity or excess weight with a related medical problem, adults lost ~35 lbs (or ~15% body weight).* People taking placebo in the study lost an average of 6 lb (or ~2.5% body weight). The average starting weight for both groups was ~232 lbs.**

**Results are from a 68-week medical study of adults with obesity (BMI ≥30) and adults with excess weight (BMI ≥27) who also had weight-related medical problems including high blood pressure or high cholesterol. 

* Individual results may vary

People respond to medicines differently, so there is no set time for when you can expect to see results with Semaglutide or Tirzepatide. Talk to our providers at Ariya Aesthetics about what might be a realistic expectation for you.*

* Individual results may vary

All our patients will be trained on proper sterile injection techniques.  It is administered once weekly, on the same day each week, at any time of day, with or without meals. Injections are given subcutaneously in the abdomen, thigh or upper arm and are mainly painless.

Most common adverse reactions are nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease, and nasopharyngitis. These side effects are usually mild to moderate and typically resolve within a few days to a few weeks*

* Individual results may vary

Semaglutide or Tirzepatide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). It is also not recommended for use in individuals with a history of pancreatitis. Also should be avoided in known hypersensitivity to any GLP-1 receptor agonists or glucose-dependent insulinotropic polypeptide (GIP) receptor agonists . Also, should not be used in patients who are pregnant or breasfeeding or trying to get pregnant.

It should not be used in combination with other glucose-dependent insulinotropic polypeptide (GIP) receptor agaonist or GLP-1 receptor agonist. Safety and efficacy of co-administration with other products for weight loss have not been established. It has not been studied in patients with a history of pancreatitis